Voriconazole therapy in children with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 4, Issue 4, 2005, Pages 215-220

  Hilliard, Tom ^a,b   Edwards, Siân ^a   Buchdahl, Roger ^a   Francis, Jacqueline ^a   Rosenthal, Mark ^a   Balfour Lynn, Ian ^a   Bush, Andrew ^a   Davies, Jane ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

Allergic bronchopulmonary aspergillosis; Antifungal agents; Cystic fibrosis; Voriconazole

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; ITRACONAZOLE; METHOTREXATE; PREDNISOLONE; VORICONAZOLE;

ADOLESCENT; ADRENAL INSUFFICIENCY; ARTICLE; ASPERGILLUS FUMIGATUS; BRONCHOPULMONARY ASPERGILLOMA; CHILD; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; ERYTHEMA; FEMALE; FUNGUS ISOLATION; HAIR LOSS; HEALTH CARE FACILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIVER DYSFUNCTION; LUNG FIBROSIS; LUNG FUNCTION; MALE; MONOTHERAPY; NAUSEA; PHOTOSENSITIVITY DISORDER; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEROLOGY; SYMPTOMATOLOGY;

ADOLESCENT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; LUNG DISEASES, FUNGAL; MALE; PYRIMIDINES; RETROSPECTIVE STUDIES; SPUTUM; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; TRIAZOLES;

EID: 29544437697     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2005.05.019     Document Type: Article

References (22)

1. J.L. Burns J. Emerson J.R. Stapp D.L. Yim J. Krzewinski L. Louden et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States Clin Infect Dis 27 1998 158-163
2. R.L. Gibson J.L. Burns B.W. Ramsey Pathophysiology and management of pulmonary infections in cystic fibrosis Am J Respir Crit Care Med 168 2003 918-951
3. G. Mastella M. Rainisio H.K. Harms M.E. Hodson C. Koch J. Navarro et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis Eur Respir J 16 2000 464-471
4. D.A. Stevens R.B. Moss V.P. Kurup A.P. Knutsen P. Greenberger M.A. Judson et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis - state of the art: Cystic Fibrosis Foundation Consensus Conference Clin Infect Dis 37 2003 S225-S264
5. B.J. Rosenstein H. Eigen Risks of alternate-day prednisone in patients with cystic fibrosis Pediatrics 87 1991 245-246
6. P.A. Wark P.G. Gibson Allergic bronchopulmonary aspergillosis: New concepts of pathogenesis and treatment Respirology 6 2001 1-7
7. M. Skov N. Hoiby C. Koch Itraconazole treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis Allergy 57 2002 723-728
8. I.B. Nepomuceno S. Esrig R.B. Moss Allergic bronchopulmonary aspergillosis in cystic fibrosis: Role of atopy and response to itraconazole Chest 115 1999 364-370
9. D.A. Stevens H.J. Schwartz J.Y. Lee B.L. Moskovitz D.C. Jerome A. Catanzaro et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis N Engl J Med 342 2000 756-762
10. P.A. Wark M.J. Hensley N. Saltos M.J. Boyle R.C. Toneguzzi G.D. Epid et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial J Allergy Clin Immunol 111 2003 952-957
11. L.B. Johnson C.A. Kauffman Voriconazole: A new triazole antifungal agent Clin Infect Dis 36 2003 630-637
12. S.P. Conway C. Etherington D.G. Peckham K.G. Brownlee A. Whitehead H. Cunliffe Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis J Antimicrob Chemother 53 2004 841-847
13. S. Maesaki J. Iwakawa Y. Higashiyama Y. Miyazaki K. Yanagihara K. Tomono et al. Antifungal activity of a new triazole, voriconazole (UK-109496), against clinical isolates of Aspergillus spp. J Infect Chemother 6 2000 101-103
14. K.L. Oakley C.B. Moore D.W. Denning In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B J Antimicrob Chemother 42 1998 91-94
15. R. Herbrecht D.W. Denning T.F. Patterson J.E. Bennett R.E. Greene J.W. Oestmann et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408-415
16. T.J. Walsh I. Lutsar T. Driscoll B. Dupont M. Roden P. Ghahramani et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children Pediatr Infect Dis J 21 2002 240-248
17. L. Chow N.E. Brown D. Kunimoto An unusual case of pulmonary invasive aspergillosis and aspergilloma cured with voriconazole in a patient with cystic fibrosis Clin Infect Dis 35 2002 e106-e110
18. K.M. Main M. Skov I.B. Sillesen H. Dige-Petersen J. Muller C. Koch et al. Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient Acta Paediatr 91 2002 1008-1011
19. J.S. Parmar T. Howell J. Kelly D. Bilton Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis Thorax 57 2002 749-750
20. E. De Wachter J. Vanbesien S.I. De A. Malfroot J. De Schepper Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide Eur J Pediatr 162 2003 488-489
21. B. Lebrun-Vignes V.C. Archer B. Diquet J.C. Levron O. Chosidow A.J. Puech et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects Br J Clin Pharmacol 51 2001 443-450
22. British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, 2004.